Patanjalis Coronil Has No Regulatory Approvals IMA

The Indian Medical Association (IMA) has stated that the Central Drugs Standard Control Organisation (CDSCO) has not given permission for the use of Patanjali’s Coronil for the treatment of Covid-19.The IMA’s statement is based on a response it received from the CDSCO against a Right to Information (RTI) application filed by the Association.The IMA added that it had raised questions on the usage of certain tablets (Coronil) as a curative medicine for the Corona infection, when it was promoted as preventive and curative medicine by the producers of the drug.“The claim as the evidenced-based drug was also questioned as the evidence cited was just a Pilot study with 45 asymptomatic patients. It was also falsely promoted as the CDSCO has given license for the drug to be used as a therapeutic drug,” the IMA stated.As for WHO certification, which is Certification of Pharmaceutical Product (CoPP), the national regulatory authority issues it for the purpose of international commerce i.e. for registration of product in foreign countries, the IMA further stated.In a letter to IMA, Sushanta Sarkar, Assistant Drugs Controller (India) said, “CDSCO has issued Certification of pharmaceutical product to Divya Pharmacy Unit (II), Haridwar for their product Divya coronil tablet, after examination of their application in consultation with the Ministry of Ayush.”“IMA acknowledges and respects the valuable contribution of pure Ayurveda drugs and their role in building immunity which will help the overall well-being. But using it as an only curative drug for infected people will be a dangerous one. In the pandemic we need to be extra cautious as any false hope will enhance the spread of the disease,” the association stated.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!